All Drug Targets articles
-
ArticleDrug discovery in Q3 2026 – what changed and why it matters
Agentic AI, ultralarge virtual screening, molecular glues and human-relevant models were among the key developments in early drug discovery during Q3 2026. Drug Target Review examines what changed, why it matters and what to watch heading into Q4.
-
ArticleInduced proximity drugs – why complex formation is not enough
A drug can form exactly the complex it was designed to make and still fail to work. Two recently approved induced proximity drugs show why what happens after complex formation – not formation alone – can decide the outcome.
-
NewsNew P. vivax vulnerability could prevent liver-stage malaria infection
A newly identified epitope on the circumsporozoite protein of Plasmodium vivax could offer a route to vaccines that prevent liver-stage infection and curb the relapse-driven transmission cycle.
-
NewsMenin inhibitor KO-7246 shows β-cell regeneration in preclinical diabetes models
New preclinical data suggests that menin inhibitor KO-7246 can regenerate functional pancreatic β-cells and sustain improvements in blood glucose control across both Type 1 and Type 2 diabetes models.
-
NewsBrain circuit linking cold exposure to metabolism identified in hypothalamus
Researchers at USF Health have identified a previously unknown brain circuit in the hypothalamus that coordinates eating behaviour, heat production and energy expenditure in response to cold, with implications for obesity and metabolic disease drug discovery.
-
NewsMathematical model probes metals’ role in Alzheimer’s plaque formation
A mathematical framework simulates how metals such as copper and zinc interact with amyloid-beta, offering a new computational tool to explore plaque formation and potential therapeutic interventions in Alzheimer’s disease.
-
ArticleAI agents vs scientists: what should we automate in drug discovery?
AI agents can search, analyse and plan across drug discovery workflows, but where should scientists hand over control? We examine what to automate, what to check and where human judgement matters most.
-
NewsHyperreactive astrocytes identified as key drivers of TSC epilepsy
Researchers at UC Berkeley have used long-term human brain organoids to show that hyperreactive astrocytes may drive the inflammation and seizures associated with tuberous sclerosis complex.
-
ArticleHow disease exposes hidden epitopes that AI models may miss
A protein can look very different in disease without a single change to its sequence. Measuring these structural changes could reveal drug targets invisible to genomic and expression data alone.
-
NewsMayo Clinic strategy restores CAR T targets on aggressive thyroid tumours
Mayo Clinic researchers have shown that approved thyroid cancer drugs can restore a key antigen on aggressive tumour cells, making them visible once more to CAR T cells and improving treatment outcomes in preclinical models.
-
NewsOestrogen receptor alpha identified as right ventricle protector in pulmonary hypertension
Scientists at National Jewish Health have identified oestrogen receptor alpha as a potential therapeutic target for preserving right ventricular function in pulmonary hypertension.
-
NewsKidney organoids reveal inflammation drives diabetic kidney disease
University of Washington researchers have used stem cell-derived kidney organoids to uncover inflammatory pathways that drive diabetic kidney disease.
-
ArticleHow protective gene variants are revealing new drug targets
Finding the right drug target remains one of discovery’s biggest challenges. Human genetics is helping researchers strengthen the evidence before committing years of research and investment.
-
NewsWhat SIRPα reveals about how breast cancer takes hold in the brain
Scientists at Wake Forest University School of Medicine have uncovered a previously unrecognised cancer-intrinsic role for SIRPα in triple-negative breast cancer, linking the cell-surface protein to mitochondrial fission, tumour-cell migration and suppression of the brain’s immune defences.
-
NewsInsilico Medicine launches open-source AI longevity research toolkit
Insilico Medicine has published a Cell cover study introducing LongevityBench, a suite of specialised AI models and an autonomous agentic discovery platform.
-
NewsWhy researchers are targeting Nav1.7 in the search for longer-lasting pain relief
Humanised antibodies targeting the voltage-gated sodium channel Nav1.7 have demonstrated prolonged suppression of neuropathic pain in a rat model.
-
NewsBacterial enzyme found to weaken gut protective hormone signal
A bacterial enzyme produced by Bacteroides vulgatus has been shown to inactivate the intestinal hormone GLP-2, disrupting gut barrier function and aggravating colitis in a preclinical model — with a natural product inhibitor identified as a potential intervention.
-
NewsSalk researchers uncover how interferons switch from anti- to pro-cancer
Researchers at the Salk Institute have identified a cellular pathway through which prolonged interferon exposure triggers mitochondrial dysfunction, PGE2 production and suppression of anti-tumour immunity – offering a potential strategy for overcoming immunotherapy resistance.
-
NewsSolute carrier transporters open new frontier in neurological drug discovery
A comprehensive review of solute carrier transporters argues that the 464-strong SLC protein family represents a largely unexplored opportunity for developing treatments across a range of neurological and psychiatric conditions, from epilepsy and autism to Alzheimer’s disease.
-
NewsOutSee secures £50k innovate UK grant for AI target validation
UK genomics and drug discovery company OutSee has received £50,000 in Innovate UK funding to develop an agentic AI sub-system designed to automate the initial triage of drug targets identified by its Nomaly genomics engine.